The clinical relevance of our data was further highlighted in a small, prospective, multicenter pilot trial on B-cell depletion with anti-CD20 antibody ofatumumab in patients with therapy-resistant advanced metastatic melanoma (see Methods, Supplementary Fig. 12; NCT01376713). The gene discussed is MS4A1; the disease is metastatic melanoma.